Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

BioCryst's Growth Story Faces Pipeline Execution and Revenue Concentration Risks

Jul 08, 2026 | Team Kalkine
BioCryst's Growth Story Faces Pipeline Execution and Revenue Concentration Risks
Image source: Shutterstock

  • BCRX:NASDAQ
  • Investment Type
    Large-cap
  • Risk Level
  • Action
  • Rec. Price (US$)

BioCryst Pharmaceuticals 

BioCryst Pharmaceuticals (NASDAQ: BCRX) is a biotechnology company focused on rare diseases, particularly hereditary angioedema (HAE). Its key product is ORLADEYO for HAE prevention, along with RAPIVAB for influenza treatment. The company also has a growing pipeline, including navenibart for HAE, BCX10013, and early-stage programs such as STAR0310 for atopic dermatitis.

As per our previous US Inflation Report published on ‘BCRX’ on April 24, 2026, we provided a ‘Buy’ stance on the stock at USD 8.66 based on “price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis” and the stock price has now moved up by ~26.90% since then and has attained resistance 1 and resistance 2.

Noted below are the details of support and resistance levels provided in our previous report:


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…